Comment
Author: Admin | 2025-04-28
THE TABLET CHOICE IN BOWEL PREPARATION See the Latest About SUTAB Download an instructional sheet Activate your savings copay card Start Here Efficacy of patients in two pivotal trials achieved successful bowel cleansing with SUTAB2,3* Tolerability of patients in one pivotal trial rated SUTAB as tolerable to very easy to consume2† 52% of all SUTAB and MoviPrep® patients reported at least one selected gastrointestinal adverse reaction2,3‡ More SUTAB patients reported experiencing nausea and vomiting than competitor, with ≤1% of these reports considered severe2,3‡ Compliance of patients in two pivotal trials were able to complete both doses of preparation2,3 Patient Acceptance Nearly 4 out of 5 patients (78%) in one pivotal trial would request SUTAB again for a future colonoscopy2† Tablets and packaging not shown actual size. *Success was the primary endpoint and was defined in non-inferiority trials as an overall cleansing assessment of 3 (good) or 4 (excellent) by the blinded endoscopist; scores were assigned following completion of the colonoscopy. †Patients completed a preference questionnaire following completion of study drug to capture their perceptions of the preparation experience. This questionnaire has not undergone formal validation. ‡Patients were queried for selected gastrointestinal adverse reactions of upper abdominal pain, abdominal distension, nausea, and vomiting following completion of study drug, rating the intensity as mild, moderate, or severe.2,3 MoviPrep is a registered trademark of Velinor AG. SEE THE LATEST ABOUT SUTAB® IN THE NEWS REVIEW THE WASHINGTON POST ARTICLE --> IMPORTANT SAFETY INFORMATION SUTAB IMPORTANT SAFETY INFORMATION INDICATION SUTAB® (sodium sulfate, magnesium sulfate,
Add Comment